Last updated 10 days ago
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC
200 patients around the world
Available in Brazil
Amgen
4Research sites
200Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
To 99 Years
All Gender
Medical requirements
- Histologically or cytologically confirmed metastatic or unresectable locally advanced MTAP-deleted non-small cell lung cancer.Participants will have received and progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.Either an archival tissue sample or an archival block must be available.Life expectancy of greater than 3 months, in the opinion of the investigator.Participants who have had brain metastases and have been appropriately treated with radiation therapy or surgery ending at least 14 days before study day 1 are eligible.Participants with untreated asymptomatic brain metastases smaller or equal to 2 cm in size per lesion if more than one and not requiring corticosteroid treatment are eligible.
- Tumors harboring the following mutations amenable to targeted therapies: epidermal growth factor receptor (EGFR), ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), MET proto-oncogene (MET), B-Raf proto-oncogene (BRAF), RET proto-oncogene (RET), Human epidermal growth factor receptor 2 (HER2), KRAS proto-oncogene (KRAS).Major surgery within 28 days of study day 1.Untreated symptomatic central nervous system metastatic disease regardless of size or asymptomatic brain metastases greater than 2 cm per lesion.
Sites
Núcleo de Oncologia da Bahia
Recruiting
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
AC Camargo Cancer Center
Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
SponsorAmgen
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
To 99 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06593522
